araag2/HINT huggingface dataset:
Clinical trial NCT00157196 (phase 2, status: completed)
Conditions: carcinoma, non-small-cell lung, lung neoplasms
ICD codes: D02.20, D02.21, D02.22, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: single low dose cyclophosphamide
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically documented unresectable stage III NSCLC. Mediastinal (N2) involvement
             must be confirmed by biopsy

          -  Stable disease or clinical response after primary therapy of chemo-radiation treatment
             for unresectable stage III disease

          -  Primary therapy should be a minimum of 2 cycles of Platinum-based first-line
             chemotherapy, given concurrent with thoracic radiation. The combined modality should
             consist of either:

               -  induction (2 cycles) chemotherapy followed by concurrent chemo-radiation therapy;
                  or

               -  concurrent chemo-radiation therapy followed by 2 cycles of consolidation
                  chemotherapy; or

               -  concurrent chemoradiation therapy alone

          -  A minimum radiation dose of greater than or equal to (>=) 6,000 centigray (cGy) should
             be administered. Subjects must have completed the primary therapy at least 4 weeks and
             no later than 6 months prior to study entry

          -  Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to
             (<=) 1

          -  Ability to understand and willingness to sign a written informed consent

          -  Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          -  Undergone lung cancer specific therapy (including surgery) prior to primary
             chemo-radiation therapy

          -  Received immunotherapy/systemic immunosuppressive drugs/investigational systemic drugs
             within 4 weeks prior to study entry

          -  Subjects with brain metastases, pleural effusion, unless cytologically confirmed to be
             non-malignant

          -  Past or current history of neoplasm other than lung carcinoma, except for curatively
             treated non-melanoma skin cancer, in situ carcinoma of the cervix or other cancer
             curatively treated and with no evidence of disease for at least 5 years

          -  Autoimmune disease or immunodeficiency

          -  Clinically significant hepatic, renal dysfunction or cardiac diseases

          -  Clinically significant active infection

          -  Pregnant or lactating, women of childbearing potential, unless using effective
             contraception as determined by the investigator

          -  Other protocol defined inclusion criteria could apply
Clinical trial NCT00389441 (phase 2, status: completed)
Conditions: thyroid neoplasms
ICD codes: C73, D34, D44.0, Z85.850
Drugs: ag-013736
SMILES: CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Radioiodine-refractory metastatic or unresectable locally-advanced thyroid cancer

          -  At least 1 measurable target lesion, as defined by RECIST

        Exclusion Criteria:

          -  Thyroid lymphoma

          -  Previous treatment with anti-angiogenesis agents

          -  No myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass
             graft, symptomatic congestive heart failure, cerebrovascular accident or transient
             ischemic attack, deep vein thrombosis or pulmonary embolism within 12 months prior.
Clinical trial NCT00002972 (phase 2, status: completed)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: paclitaxel
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically proven bronchoalveolar carcinoma (BAC) based on these criteria:

               -  Absence of primary adenocarcinoma elsewhere

               -  Absence of a demonstrable central bronchogenic origin

               -  A peripheral location in the lung parenchyma

               -  Intact interstitial framework of the lung

               -  A histological appearance setting it apart from other tumors, with a
                  characteristic pattern of growth: cuboidal or cylindrical cells lining up the
                  alveolar septa with preservation of basic pulmonary architecture

          -  Must be unresectable Stage IIIB, IV, or recurrent BAC

          -  Evidence of multinodular lesions involving the lungs bilaterally or unilaterally (in
             the latter the lesions must involve more than one lobe)

          -  At least one target lesion bidimensionally measurable that has not undergone prior
             irradiation

          -  No CNS disease

        PATIENT CHARACTERISTICS:

        Age:

          -  18 to 75 (inclusive)

        Performance status:

          -  ECOG 0-2

        Life expectancy:

          -  Greater than 3 months

        Hematopoietic:

          -  ANC at least 1,500/mm^3

        Hepatic:

          -  Bilirubin less than 2 times upper limit of normal

          -  SGOT, SGPT, and alkaline phosphatase less than 2 times upper limit of normal

        Renal:

          -  Creatinine less than 1.5 times upper limit of normal

        Cardiovascular:

          -  No history of ischemic or congestive heart disease

          -  No arrhythmia requiring chronic cardiopulmonary medications

          -  No history of clinically or electrographically documented myocardial infarction

        Other:

          -  No preexisting motor or other serious sensory neurotoxicity

          -  No active or prior second primary cancer except basal cell carcinoma of the skin or
             carcinoma in situ of the cervix

          -  No clinical evidence of uncontrolled infection

          -  Not pregnant or nursing

          -  Negative pregnancy test 72 hours prior to start of study medication

          -  Adequate contraception required of all fertile patients

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No prior chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  At least 4 weeks since radiotherapy

          -  Must have at least one bidimensional lesion outside the irradiated fields

        Surgery:

          -  Fully recovered from any prior major surgery
Clinical trial NCT01466790 (phase 2, status: completed)
Conditions: hepatitis c
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: tmc435, psi-7977 (gs7977), ribavirin
SMILES: [H]\C1=C([H])\[C@]2([H])C[C@]2(N=C(O)[C@]2([H])C[C@]([H])(C[C@@]2([H])C(=O)N(C)CCCC1)OC1=C2C=CC(OC)=C(C)C2=NC(=C1)C1=NC(=CS1)C(C)C)C(O)=NS(=O)(=O)C1CC1, CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Chronic genotype 1 hepatitis C virus (HCV) infection

          -  Plasma HCV RNA of more than 10,000 IU/mL at screening

          -  Patients in Cohort 1 must be null responders to PegIFN/ribavirin with at least 1
             documented previous course of PegIFN/ribavirin therapy for at least 12 consecutive
             weeks

          -  Patients in Cohort 2 must be null responders to PegIFN/ribavirin with at least 1
             documented previous course of PegIFN/ribavirin therapy for at least 12 consecutive
             weeks and could also be HCV treatment-naive, meaning never received treatment with any
             approved or investigational drug for the treatment of HCV

          -  Null responders patients in Cohort 1 and Cohort 2 must meet the defined criterion for
             a null responder, defined as on-treatment less than 2 log10 IU/mL reduction in HCV RNA
             from baseline at Week 12 of the most recent PegIFN/ribavirin therapy

          -  Patient must have had a liver biopsy within 3 years before screening (or between
             screening and baseline visit) or patient must have had a liver biopsy at any time in
             the past which showed Metavir F3 or F4 fibrosis

          -  Must agree to use 2 forms of effective contraception throughout the study (male and
             female)

        Exclusion Criteria:

          -  Has evidence of hepatic decompensation

          -  Has any liver disease of non-HCV etiology

          -  Has an infection/co-infection with non-genotype 1 HCV

          -  Has a co-infection with Human immunodeficiency virus (HIV) type 1 or type 2 (HIV-1 or
             HIV-2) (positive HIV-1 or HIV-2 antibody test at screening)

          -  Has a co-infection with hepatitis B virus (hepatitis B surface antigen [HBsAg]
             positive)

          -  Has a history of malignancy within 5 years of the screening visit
Clinical trial NCT00199433 (phase 2, status: completed)
Conditions: parkinson's disease, movement disorder syndrome
ICD codes: G20
Drugs: istradefylline (kw-6002)
SMILES: [H]\C(=C(\[H])C1=CC(OC)=C(OC)C=C1)C1=NC2=C(N1C)C(=O)N(CC)C(=O)N2CC
Eligibility criteria:

        Inclusion Criteria:

          1. Early PD by UKPDS criteria

          2. Mild to moderate difficulty daily activities

          3. Females: Either postmenopausal or willing to use adequate contraception

        Exclusion Criteria:

          1. Unable to discontinue current PD medication

          2. Exposure to Levodopa for more than 1 month

          3. Symptoms that may suggest a diagnosis other than Parkinson's disease

          4. Medical conditions and/or abnormal laboratory findings which preclude participation
             including cancer in the last 5 years, a history of drug abuse/dependence, abnormal
             cognitive status, a history of seizures, neuroleptic malignant syndrome, psychosis, or
             abnormal liver function tests
Clinical trial NCT00403845 (phase 2, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: indacaterol 150 μg, indacaterol 300 μg, placebo
SMILES: CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1, CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female Japanese aged 40 to 75 years old

          -  Moderate to severe chronic obstructive pulmonary disease (COPD) with smoking history
             of at least 20 pack years

        Exclusion Criteria:

          -  History of hospitalization for COPD exacerbation within past 6 months

          -  Use of long-term oxygen therapy

          -  History of asthma

          -  Respiratory tract infection within past 1 month

          -  Consistently very high or low blood sugar

          -  Clinically abnormal laboratory values or significant condition

          -  History of heart failure or heart attack within past 6 months

          -  History of long QT syndrome or long QT interval in electrocardiogram recorded at
             screening

        Other protocol-defined inclusion/exclusion criteria applied to the study.
Clinical trial NCT00573469 (phase 2, status: completed)
Conditions: crohn's disease
ICD codes: K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919
Drugs: d9421-c, 9mg, d9421-c, 15mg, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Female or male aged ≥ 18 and ≤ 65 years

          -  Diagnosis of Crohn's Disease

        Exclusion Criteria:

          -  Having ileostomy or pouch and/or colostomy

          -  Having previous gastric surgery

          -  Having a known or suspected systemic infection
Clinical trial NCT01024504 (phase 2, status: completed)
Conditions: metastatic colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: oxaliplatin, capecitabine, bevacizumab
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the colon or rectum

          -  Stage IV

          -  Existence of two-dimensional measurable disease. The measurable disease should not
             have been irradiated.

          -  Absence or irradiated and stable central nervous system metastatic disease.

          -  Life expectancy of more than 3 months.

          -  Age ≥ 70 years.

          -  Performance status (WHO) ≤ 2.

          -  Adequate bone marrow function (Absolute neutrophil count >1000/mm3, Platelet count
             >100000/mm3, Hemoglobin >9gr/mm3).

          -  Adequate liver (Bilirubin <1.5 times upper limit of normal and SGOT/SGPT <2 times
             upper limit of normal).

          -  Creatinine clearance (Cockcroft-Gault formula) >30ml/min.

          -  No other invasive malignancy within the past 5 years except nonmelanoma skin cancer.

          -  Presence of a reliable care giver.

          -  Informed consent.

        Exclusion Criteria:

          -  Prior chemotherapy for metastatic disease.

          -  History of thromboembolic disease or myocardial infraction within the last 6 months.

          -  Peripheral neuropathy ≥ grade 2.

          -  Bowel obstruction or chronic diarrhea.

          -  Psychiatric illness or social situation that would preclude study compliance.

          -  Other concurrent uncontrolled illness.

          -  Other concurrent investigational agents.
Clinical trial NCT00038298 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: placebo, amg 719, agm 719, amg 719, placebo to amg 719
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        -  Men or women, at least 18 years of age at screening

          -  Diagnosed with Rheumatoid Arthritis, with a disease duration of at least 24 weeks,
             receiving methotrexate, and having no recent history of substance or alcohol abuse
Clinical trial NCT01033084 (phase 2/phase 3, status: completed)
Conditions: depressive disorder, major
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: sertraline
SMILES: CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Depressive Disorder, Major (SCID)

          -  HDRS > 18

        Exclusion Criteria:

          -  Other axis I disorders, including Bipolar Disorder, Schizophrenia, Substance Abuse
             Disorders.

          -  Any axis II disorders.

          -  Any serious/life-threatening axis III disorders, such as Congestive Heart Failure,
             Pulmonary Obstructive Chronic Disease, Active Neoplasia.

          -  Neurological diseases such as Stroke (and Post-Stroke Depression), Dementias and
             others.
Clinical trial NCT01327053 (phase 2, status: completed)
Conditions: basal cell carcinoma
ICD codes: C44.510, C44.91, C44.01, C44.311, C44.511, C44.81, C44.41
Drugs: lde225
SMILES: [H][C@]1(C)CN(C[C@@]([H])(C)O1)C1=CC=C(NC(=O)C2=CC=CC(=C2C)C2=CC=C(OC(F)(F)F)C=C2)C=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with locally advanced BCC and metastatic BCC

          -  Patients with adequate bone marrow, liver, and renal function

        Exclusion Criteria:

          -  Patients who had had major surgery within 4 weeks of initiation of study medication

          -  Patients unable to take oral drugs or with lack of physical integrity of the upper
             gastrointestinal tract, or known malabsorption syndromes.

          -  Patients with concurrent medical conditions that may interfere or potentially affect
             the interpretation of the study.

          -  Patients with neuromuscular disorders or are on concurrent treatment with drugs that
             may cause muscle damage.

          -  Patients who were on concurrent therapy with other anti-neoplastic agents.

          -  Patients who had taken part in an experimental drug within 4 weeks of initiation of
             study medication.

          -  Pregnant or nursing (lactating) women

          -  Women of child bearing potential unwilling to use 2 forms of highly effective
             contraception throughout the study and for 3 months after the last treatment

          -  Fertile males not willing to use condoms throughout the study and for 3 months after
             the last treatment.

          -  Patients who were unwilling or unable to comply with the protocol.
Clinical trial NCT00400439 (phase 2, status: completed)
Conditions: coronary heart disease
ICD codes: I25.10, I25.110, I25.119, I25.111, I25.118
Drugs: dalcetrapib (ro4607381), placebo
SMILES: CCC(CC)CC1(CCCCC1)C(=O)NC1=CC=CC=C1SC(=O)C(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  patients who have completed treatment on study NC19453.

        Exclusion Criteria:

          -  any significant lymph node abnormalities at the end of study NC19453.
Clinical trial NCT00337090 (phase 2, status: completed)
Conditions: overactive bladder
ICD codes: N32.81
Drugs: ym178
SMILES: NC1=NC(CC(=O)NC2=CC=C(CCNC[C@H](O)C3=CC=CC=C3)C=C2)=CS1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients over 18 years suffering from overactive bladder (OAB) for more than 3 months

        Exclusion Criteria:

          -  Pregnant and breastfeeding women

          -  Any medical condition or need for co-medication which interferes with the drug under
             investigation (YM178) or the comparator (tolterodine)
Clinical trial NCT00672334 (phase 2/phase 3, status: terminated)
Conditions: cardiac surgery, cardiopulmonary bypass
ICD codes: I97.110, I97.120, I97.710, I97.190, I97.790, I97.111, I97.121, Q93.81, B33.4, A36.81, A50.54, A52.00, A52.09, B33.24
Drugs: sodium bicarbonate, sodium chloride
SMILES: [Na+].OC([O-])=O, [Na+].[Cl-]
Eligibility criteria:

        Inclusion Criteria:

          -  Cardiac surgical patients in whom the use of cardiopulmonary bypass was planned and:

          -  Written informed consent of patient

          -  Age >18 years

          -  And having at least one ore more of the following risk factors for postoperative AKI:

               -  Age =/>70 years

               -  Preoperative plasma creatinine >120 µmol/L New York Heart Association class III /
                  IV or LVEF <35%

               -  Insulin dependent diabetes mellitus

               -  Valve surgery (with or without coronary artery bypass graft)

               -  Redo cardiac surgery

        Exclusion Criteria:

          -  Cardiac surgical patients will not be considered eligible if:

          -  An emergency operation is indicated (within 24 hours after hospital admission or on
             intra-aortic balloon pump) or

          -  Pregnancy is confirmed or breastfeeding is present or

          -  A renal allograft is present or

          -  Preoperative acute renal failure within 6 weeks (acute rise in serum creatinine >50%
             from baseline) is present or

          -  Pre-operative end stage renal disease (serum creatinine >300 µmol/L) is present or

          -  Chronic moderate to high dose corticosteroid therapy (>10 mg/d prednisone or
             equivalent) is present
Clinical trial NCT01474239 (phase 2, status: completed)
Conditions: glioblastoma multiforme
ICD codes: L51.0, L51.8, L51.9
Drugs: bevacizumab [avastin], fotemustine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CCOP(=O)(OCC)[C@@H](C)NC(=O)N(CCCl)N=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients, >/=18 years of age

          -  Diagnosis of recurrent glioblastoma multiforme (Grade IV)

          -  Previous treatment with temozolomide and radiotherapy

          -  First recurrence after standard adjuvant treatment (surgery, followed by radiotherapy
             and chemotherapy)

          -  Adequate hematological, biochemical and organ functions

        Exclusion Criteria:

          -  Previous treatment with Avastin or other anti-angiogenic drugs

          -  Residual relevant toxicity resulting from previous therapy

          -  Radiotherapy within the 3 months prior to the diagnosis of disease progression

          -  Chemotherapy in the previous 4 weeks

          -  Other active or inactive malignancies (except for carcinoma in situ of the cervix, of
             the prostate or basal cell carcinoma)

          -  Clinically significant cardiovascular diseases
Clinical trial NCT00572455 (phase 2, status: completed)
Conditions: primary open angle glaucoma, ocular hypertension
ICD codes: H40.1130, H40.1131, H40.1132, H40.1133, H40.1134, H40.1110, H40.1111, H40.053, H40.051, H40.052, H40.059
Drugs: pf-04217329 - lowest dose, pf-04217329 - low dose, pf-04217329 - middle dose, pf-04217329 - high middle dose, pf-04217329 - high dose, pf-4217329 - highest dose, pf-04217329 - vehicle, latanoprost vehicle, pf-04217329 - low dose, latanoprost vehicle, pf-04217329 - middle dose, latanoprost vehicle, pf-04217329 - high dose, latanoprost 0.005%, pf-04217329 - low dose, latanoprost 0.005%, pf-04217329 - middle dose, latanoprost 0.005%, pf-04217329 - high dose, latanoprost 0.005%, pf-04217329 - vehicle
SMILES: OC(=O)COC1=CC=CC(CN(CC2=CC=C(C=C2)N2C=CC=N2)S(=O)(=O)C2=CC=CN=C2)=C1, OC(=O)COC1=CC=CC(CN(CC2=CC=C(C=C2)N2C=CC=N2)S(=O)(=O)C2=CC=CN=C2)=C1, OC(=O)COC1=CC=CC(CN(CC2=CC=C(C=C2)N2C=CC=N2)S(=O)(=O)C2=CC=CN=C2)=C1, OC(=O)COC1=CC=CC(CN(CC2=CC=C(C=C2)N2C=CC=N2)S(=O)(=O)C2=CC=CN=C2)=C1, OC(=O)COC1=CC=CC(CN(CC2=CC=C(C=C2)N2C=CC=N2)S(=O)(=O)C2=CC=CN=C2)=C1, OC(=O)COC1=CC=CC(CN(CC2=CC=C(C=C2)N2C=CC=N2)S(=O)(=O)C2=CC=CN=C2)=C1, CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1, OC(=O)COC1=CC=CC(CN(CC2=CC=C(C=C2)N2C=CC=N2)S(=O)(=O)C2=CC=CN=C2)=C1, CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1, OC(=O)COC1=CC=CC(CN(CC2=CC=C(C=C2)N2C=CC=N2)S(=O)(=O)C2=CC=CN=C2)=C1, CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1, OC(=O)COC1=CC=CC(CN(CC2=CC=C(C=C2)N2C=CC=N2)S(=O)(=O)C2=CC=CN=C2)=C1, CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1, OC(=O)COC1=CC=CC(CN(CC2=CC=C(C=C2)N2C=CC=N2)S(=O)(=O)C2=CC=CN=C2)=C1, CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1, OC(=O)COC1=CC=CC(CN(CC2=CC=C(C=C2)N2C=CC=N2)S(=O)(=O)C2=CC=CN=C2)=C1, CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1, OC(=O)COC1=CC=CC(CN(CC2=CC=C(C=C2)N2C=CC=N2)S(=O)(=O)C2=CC=CN=C2)=C1, CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1, OC(=O)COC1=CC=CC(CN(CC2=CC=C(C=C2)N2C=CC=N2)S(=O)(=O)C2=CC=CN=C2)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of primary open-angle glaucoma (including pigmentary or pseudoexfoliative)
             or ocular hypertension in 1 or both eyes.

          -  Qualifying intraocular pressure (IOP) in the same eye at the Eligibility 1 and 2
             measurements.

        Exclusion Criteria:

          -  Closed/barely open anterior chamber angle or a history of acute angle closure in
             either eye.

          -  Anticipate the need to initiate or modify medication (systemic or topical) that is
             known to affect intraocular pressure (IOP) during the study period.